Page 255 - Drug Class Review
P. 255
Drug Effectiveness Review Project
Groups similar at baseline: Yes, although 10 percentage point difference in sex
Alzheimer classification: Mild-moderate
Health Outcome Measures: Outcome Measures: 0.054)
donepezil placebo 72.9 72.1 59 69.7 100 100 19.26 19.37 29.77 29.51 4.16 4.15 11.78 13.05 Primary Outcome Measures: GBS total score plus the 4 domains: GBS-I (intellectual), GBS-ADL (activities of daily living), GBS-E (reasoning), GBS-S (behavior) Secondary Outcome Measures: MMSE; ADL; PDS; NPI; GDS Timing of assessments: Weeks 4, 12, 36 and 52 No significant differences in GBS-ADL, GBS-E, or GBS-S subtotals at endpoint Treatment response to DON was not predicted by APOE genotype or sex Significantly slower decline in PDS total score for DO
• • • • • • • •
Final Report Update 1 Author: Winblad et al. Year: 2001 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity (% white): Other germane population qualities: Mean baseline MMSE • Mean baseline GBS • Mean baseline GDS • Mean baseline NPI • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs
